Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formation
- PMID: 18752684
- PMCID: PMC2538502
- DOI: 10.1186/1477-9560-6-12
Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formation
Abstract
Objectives: To analyse the effects of rosiglitazone administered at different times on neointimal formation in hypercholesterolemic rabbits following vascular injury.
Methods: Thirty-nine rabbits on a hypercholesterolemic diet were included. The animals underwent balloon catheter injury to the right iliac artery on day 14. They were divided into three groups as follows: control group, 13 rabbits without rosiglitazone; group I, 13 rabbits treated with rosiglitazone (3 mg/Kg body weight/day) for 28 days after the vascular injury; and group II, 13 rabbits treated with rosiglitazone (3 mg/Kg body weight/day) during all the experiment (42 days). Histological analysis was done by an experienced pathologist who was unaware of the rosiglitazone treatment. Histomorphometric parameters were performed by calculation of the luminal and intimal layer area, and intima/media layer area ratio (the area of the intimal layer divided by the area of the medial layer).
Results: Intimal area was significantly lower in group II vs. CG (p = 0.024) and group I (p = 0.006). Luminal layer area was higher in group II vs. CG (p < 0.0001) and group I (p < 0.0001). Intima/media layer area ratio was equal between CG and group I. Intima/media layer ratio area was significantly lower in group II vs. control group (p < 0.021) and group I (p < 0.003). There was a significant reduction of 65% and 71% in intima/media layer area ratio in group II vs. control group and group I, respectively.
Conclusion: Pretreatment with rosiglitazone in hypercholesterolemic rabbits submitted to vascular injury significantly reduces neointimal formation.
Figures
References
-
- Phillips JW, Barringhaus KG, Sanders JM, Yang Z, Chen M, Hesselbacher S, Czarnik AC, Ley K, Nadler J, Sarembock IJ. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation. 2003;108:1994–1999. doi: 10.1161/01.CIR.0000092886.52404.50. - DOI - PubMed
-
- Seki N, Bujo H, Jiang M, Shibasaki M, Takahashi K, Hashimoto N, Saito Y. A potent activator of PPARα and γ reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits. Atherosclerosis. 2005;178:1–7. doi: 10.1016/j.atherosclerosis.2004.08.015. - DOI - PubMed
-
- Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, Jandeleit-Dahm KA, Allen TJ. Rosiglitasone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol. 2005;25:1903–1909. doi: 10.1161/01.ATV.0000177813.99577.6b. - DOI - PubMed
-
- Badimon JJ, Fernadez-Ortiz A, Meyer B, Mailhac A, Fallon JT, Falk E, Badimon L, Chesebro JH, Fuster V. Different response to balloon angioplasty of carotid and coronary arteries: Effects on acute platelet deposition and intimal thickening. Atherosclerosis. 1998;140:307–314. doi: 10.1016/S0021-9150(98)00134-8. - DOI - PubMed
LinkOut - more resources
Full Text Sources
